Evaluation of Effect of pioglitazone on decreasing of proteinuria in type II diabetic patients with nephropathy.

Evaluation of Effect of pioglitazone on decreasing of proteinuria in type II diabetic patients and kidney disease.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017080210222N10

Enrollment

Registered

2017-08-17

Start date

2017-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy. E10.2

Interventions

In the second group receive placebo daily orally

Intervention 1: In the first group receive tablet 30 mg pioglitazone daily orally. Intervention 2: In the second group receive placebo daily orally.

Treatment - Drugs

In the first group receive tablet 30 mg pioglitazone daily orally

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclution Criteria: 24-hour urine protein over 250 mg / day or the ratio of albumin to creatinine over 30 mg/g Exclusion Criteria: Hypothyroidism and heart failure; HbA1C is less than 8; Blood pressure less than 160/100; Creatinine less than 2; GFR greater than 50

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
24-hour urine protein. Timepoint: 2 month after intervention. Method of measurement: sampling.	—

Secondary

Measure	Time frame
Albumin level. Timepoint: 2month after intervention. Method of measurement: sampling.;Creatinin level. Timepoint: 2month after intervention. Method of measurement: sampling.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Momeny

Shahrekord University of Medical Sciences

Ali.momeny.dr@gmail.com+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026